Our recent publication reveals the remarkable efficacy of iPLUS in a diverse array of expression platforms and in the yield of Trastuzumab, Spike and MAGEC2, a tumor-specific antigen tested for cancer mRNA vaccines.
February 29, 2024by iPLUS
HomeCategory
